论文部分内容阅读
自体LAK细胞和rhIL-2联合应用于化疗失败或不能耐受的晚期实体瘤病人,已取得了确切的疗效,但由于取血量大及大剂量应用IL-2的严重副反应,致使其应用受限,治疗中的死亡率高,而克隆化LAK细胞具有增殖力强,体外存活期长和长时间保存有效杀瘤活性的特点。我们自1991年开始应用军医科院采用半固体一液体两步法培养的克隆化自体LAK细胞治疗15例晚期肺癌病人,取得了一定的疗效,其中Ⅲ期5例,Ⅳ期10例,治疗方法采用静脉回输克隆化自体LAK细胞,平均每次LAK量为4.7×10~8,9次为一疗程,每疗程LAK细胞总量为5×10~9,完成一疗程治疗后休息1月以上,依患者自身情况选择继续治疗并追踪观察3月。治疗者中2例未完成1疗程的治疗,13例完成1个以上治疗周期。完成治疗者中,腺癌9例、小细胞癌2例、鳞癌2例。观察结果示:9例腺癌病人中,1例部分缓解,胸水消失,8例病情稳定无进展;2例小细胞癌中,1例完全缓解,缓解期达30月,1例呈部分缓解;2例鳞癌癌者中,1例无变化,另1例病情进展,于治疗后8个月死亡。治疗总缓解率达23.1％,病情稳定率:73.3％,患者全身状况明显改善。
The use of autologous LAK cells combined with rhIL-2 in patients with advanced solid tumors that have failed or failed to tolerate chemotherapy has yielded definitive results, but its use has been due to high blood volume and severe side effects of large doses of IL-2. Restricted, the mortality rate during treatment is high, and cloned LAK cells have the characteristics of strong proliferation, long survival in vitro and long-term preservation of effective tumoricidal activity. Since 1991, we have applied the cloned autologous LAK cells cultivated by the Military Medical Academy in a semisolid-liquid two-step process to treat 15 patients with advanced lung cancer, and achieved certain curative effects, including 5 in stage III and 10 in stage IV. Intravenously reconstituted autologous LAK cells with an average of 4.7×10-8 LAKs each time, 9 times as a course of treatment, the total amount of LAK cells per treatment course is 5×10-9, and the rest after one course of treatment is more than one month. , According to the patient’s own situation, choose to continue treatment and follow up and observe in March. Among the treatment patients, 2 patients did not complete 1 course of treatment, and 13 patients completed 1 or more treatment cycles. Of the patients who completed the treatment, there were 9 cases of adenocarcinoma, 2 cases of small cell carcinoma, and 2 cases of squamous cell carcinoma. The observation results showed that in 9 cases of adenocarcinoma patients, 1 had partial remission, pleural effusion disappeared, and 8 cases had stable disease without progression. In 2 cases of small cell carcinoma, 1 case had complete remission, remission period reached 30 months, and 1 case showed partial remission. Of the 2 cases of squamous cell carcinoma, 1 had no change, and the other 1 had advanced disease and died 8 months after treatment. The total remission rate for treatment was 23.1%, and the disease stability rate was 73.3%. The general condition of patients was significantly improved.